A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.

@article{Widemann2012API,
  title={A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.},
  author={Brigitte C Widemann and AeRang Kim and Elizabeth Fox and Sylvain Baruchel and Peter C. Adamson and Ashish Mark Ingle and Julia L. Glade Bender and Michael Burke and Brenda Weigel and Diana Stempak and Frank M Balis and Susan M. Blaney},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2012},
  volume={18 21},
  pages={6011-22}
}
PURPOSE To determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of sorafenib in children with refractory extracranial solid tumors and evaluate the tolerability of the solid tumor MTD in children with refractory leukemias. EXPERIMENTAL DESIGN Sorafenib was administered orally every 12 hours for consecutive 28-day cycles. Pharmacokinetics (day 1 and steady-state) and pharmacodynamics were conducted during cycle 1. RESULTS Of 65… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
31 Citations
31 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

  • ChengAL, KangYK, ChenZ, TsaoCJ, S Qin, KimJS
  • Lancet Oncol 2009;10:25–34
  • 2012
Highly Influential
10 Excerpts

Similar Papers

Loading similar papers…